Reshma Mahtani
Chief of Breast Medical Oncology
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
mTTNT benefit in clinical subgroups: ( A ) 1–2 prior lines of ET ± CDK4/6i, ( B ) 1–2 prior lines of ET ± CDK4/6i ≥ 12 months, ( C ) 1 prior line of ET ± CDK4/6i, ( D ) 2 prior lines of ET ± CDK4/6i, ( E ) ≥3 prior lines of ET ± CDK4/6i, ( F ) visceral metastasis, ( G ) coexisting ESR1 and PI3K pathway mutations, ( H ) no prior fulvestrant, and ( I ) no prior chemotherapy.
Year:
2026
Purpose: The EMERALD trial led to the approval of elacestrant for estrogen receptor (ER)–positive, HER2-negative, estrogen receptor 1 ( ESR1 )–mutated advanced or metastatic breast cancer (mBC) with disease progression following at least one line of endocrine therapy (ET). Subgroup analyses provided evidence suggesting that elacestrant enables ET sequencing in the second line before other targeted combinations, which could delay chemotherapy-based regimens. Experimental Design: This study used claims data from the Komodo Research Dataset linked with Foundation Medicine Inc. clinical genomic data from patients with estrogen receptor+/HER2− mBC harboring an ESR1 mutation treated with elacestrant. The primary outcome measure was time to next treatment (TTNT). Results: Among 306 patients, 93.8% had prior ET ± cyclin-dependent kinase 4/6 inhibitor for ≥12 months, 50.0% had prior chemotherapy, and 72.2% had prior fulvestrant. Median TTNT (mTTNT) was 8.2 months [95% confidence interval (CI), 6.3–13.0] in patients with 1 to 2 prior lines and 7.5 months (95% CI, 7.1–9.9) in those with ≥3 prior lines of ET. In patients with coexisting ESR1 - and PI3K-pathway–mutated tumors, mTTNT was 6.3 months (95% CI, 4.8–7.9). mTTNT was 7.9 months (95% CI, 7.1–9.8) in all patients and was also sustained in patients with no prior fulvestrant [12.9 months (95% CI, 7.2–not reached)], no prior chemotherapy [8.4 months (95% CI, 7.1–13.3)], visceral metastasis [7.9 months (95% CI, 7.0–9.9)], and liver metastases [7.2 months (95% CI, 6.3–9.0)]. Conclusions: Elacestrant demonstrated a durable benefit in real-world clinical practice, particularly in earlier lines and in patients with prolonged prior ET exposure. Despite coexisting ESR1 and PI3K pathway mutations, TTNT remained clinically meaningful, reinforcing the role of elacestrant in personalized ET sequencing strategies prior to chemotherapy, antibody–drug conjugates, or targeted combinations. See related article by Lloyd et al., p. 169
Year:
2026
Purpose: Circulating tumor cells (CTC) are biomarkers associated with poor prognosis and treatment resistance in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer (MBC). This analysis evaluates the prognostic role of baseline CTC enumeration and its interaction with treatment regimens in patients progressing on CDK4/6 inhibitors. Experimental Design: The PACE trial is a phase II, multicenter, randomized study of patients with HR+/HER2− MBC experiencing progression on aromatase inhibitors and CDK4/6 inhibitors. Patients were randomized 1:2:1 to receive fulvestrant (F), F + palbociclib (F + P), or F + P + avelumab (F + P + A). Baseline CTCs were enumerated using CellSearch with a threshold of ≥5 CTCs/7.5 mL to classify patients as stage IV indolent or stage IV aggressive . Concurrent ctDNA analysis was performed using Guardant360. Progression-free survival (PFS) was the primary endpoint. Results: Among 220 randomly assigned patients, 203 were evaluable for baseline CTCs; 76% had detectable CTCs and 49% were stage IV aggressive . Patients with de novo MBC were more frequently stage IV aggressive (47.5% vs. 30.8%). Baseline CTCs were prognostic with median PFS of 5.7 months for stage IV indolent and 3.5 months for stage IV aggressive patients [HR = 1.69; 90% confidence interval (CI), 1.27–2.24; P aggressive patients, F + P and F + P + A improved PFS versus fulvestrant alone (HR = 0.43; 90% CI, 0.25–0.71 and HR = 0.26; 90% CI, 0.14–0.49, respectively). No benefit was observed in stage IV indolent patients (interaction P = 0.0148 and P = 0.0033, respectively). Conclusions: Baseline CTC enumeration provides significant prognostic information in HR+/HER2− MBC. Stage IV aggressive patients derive greater benefit from F + P or F + P + A over fulvestrant alone, independent of clinical or ctDNA features. This highlights the potential of CTCs to guide treatment decision-making.
Year:
2025
Multivariable Cox regression in terms of PFS. CTCs enumeration was corrected for ESR1, PIK3CA, RB1 mutational status and clinically relevant features (i.e., visceral involvement, duration of prior CDK4/6 inhibitor, endocrine sensitivity, therapy between prior CDK4/6i and randomization).
Year:
2025
PACE Trial Schema. Total planned enrollment was 220 patients. Primary objective: superiority of fulvestrant+palbociclib vs fulvestrant alone (A). Secondary objective: superiority fulvestrant+palbociclib+avelumab vs fulvestrant alone (B).
Year:
2025
Collaborators (14)
Carolina Reduzzi
Assistant Professor
Weill Cornell Medicine
Priyanka Sharma
Associate Professor
University of Kansas Medical Center
Angela DeMichele
University of Pennsylvania
Cynthia X. Ma
Washington University in Saint Louis School of Medicine
Yara G Abdou
University of North Carolina at Chapel Hill
Maryam Lustberg
Yale University
Harold Burstein
Professor
Dana-Farber Cancer Institute
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Sonya Reid
Vanderbilt University Medical Center
Rubina Qamar
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Kathy Miller
Indiana University Bloomington
Virginia Kaklamani
Professor
University of Texas Health Science Center at San Antonio
Erica Mayer
Dana-Farber Cancer Institute
Massimo Cristofanilli
Professor of Medicine
Weill Cornell Medicine
Make your next move.
Prepare your application
Review drafts before you send them.